Literature DB >> 28657375

Metabolic effect of obesity on polycystic ovary syndrome in adolescents: a meta-analysis.

Li Li1, Qiong Feng1, Ming Ye1, Yaojuan He1, Aling Yao2, Kun Shi1.   

Abstract

This meta-analysis provides an updated and comprehensive estimate of the effects of obesity on metabolic disorders in adolescent polycystic ovary syndrome (PCOS). Relevant articles consistent with the search terms published up to 31 January 2014 were retrieved from PubMed, EMBASE, PsycINFO and CENTRAL. Thirteen articles (16 independent studies) conformed to the inclusion criteria. The evaluated outcomes were the metabolic parameters of obese adolescents with PCOS (case group) relative to normal-weight adolescents with PCOS, or obese adolescents without PCOS. Compared with normal-weight adolescents with PCOS, the case group had significantly lower sex hormone-binding globulin and high-density lipoprotein cholesterol, and significantly higher triglycerides, leptin, fasting insulin, low-density lipoprotein cholesterol and free testosterone levels. Relative to obese adolescents without PCOS, the case group had significantly higher fasting insulin, low-density lipoprotein cholesterol, free testosterone levels and 2-h glucose during the oral glucose tolerance test. These results indicate that metabolic disorders in adolescent PCOS are worsened by concomitant obesity. This study highlights the importance of preventing obesity during the management of adolescent PCOS. Impact statement What is already known about this subject: Obesity and PCOS share many of the same metabolic disorders, for example, hyperandrogenism and hyperinsulinemia with subsequent insulin resistance. Knowledge regarding metabolic features in obese adolescents with PCOS is limited, and there is concern whether obesity and PCOS are related. What do the results of this study add: Relative to PCOS adolescents of normal weight, obese adolescents with PCOS (the case group) had significantly lower SHBG and HDL-C, and significantly higher triglycerides, leptin, fasting insulin, LDL-C and free testosterone levels. The results indicate that metabolic disorders in adolescent PCOS are worsened by concomitant obesity. What are the implications of these findings for clinical practice and/or further research: Obesity, metabolic disorders and PCOS in adolescents are associated. Obesity exacerbates metabolic disorders in adolescent PCOS. This study highlights the importance of preventing obesity during the management of adolescent PCOS. Therapeutic intervention combined with lifestyle modification may provide better treatment for adolescent PCOS. The aetiologies of PCOS combined with obesity in adolescents require further investigation.

Entities:  

Keywords:  Adolescent; PCOS; meta-analysis; metabolic syndrome; obesity; polycystic ovary syndrome

Mesh:

Substances:

Year:  2017        PMID: 28657375     DOI: 10.1080/01443615.2017.1318840

Source DB:  PubMed          Journal:  J Obstet Gynaecol        ISSN: 0144-3615            Impact factor:   1.246


  15 in total

Review 1.  Role of sex hormone-binding globulin in the free hormone hypothesis and the relevance of free testosterone in androgen physiology.

Authors:  L Antonio; D Vanderschueren; N Narinx; K David; J Walravens; P Vermeersch; F Claessens; T Fiers; B Lapauw
Journal:  Cell Mol Life Sci       Date:  2022-10-07       Impact factor: 9.207

2.  Evaluating 12 Years of Implementing a Multidisciplinary Specialist Child and Adolescent Obesity Treatment Service: Patient-Level Outcomes.

Authors:  Cathy Wyse; Lucinda Case; Órla Walsh; Catherine Shortall; Norah Jordan; Lois McCrea; Grace O'Malley
Journal:  Front Nutr       Date:  2022-06-03

3.  The comparative effectiveness of 55 interventions in obese patients with polycystic ovary syndrome: A network meta-analysis of 101 randomized trials.

Authors:  Mohamed Abdel-Maboud; Amr Menshawy; Elfatih A Hasabo; Mohamed Ibrahim Abdelraoof; Mohamed Alshandidy; Muhammad Eid; Esraa Menshawy; Oumaima Outani; Ahmed Menshawy
Journal:  PLoS One       Date:  2021-07-19       Impact factor: 3.240

4.  Circulating resistin and follistatin levels in obese and non-obese women with polycystic ovary syndrome: A systematic review and meta-analysis.

Authors:  Tahereh Raeisi; Hossein Rezaie; Mina Darand; Akram Taheri; Nazila Garousi; Bahman Razi; Leonardo Roever; Reza Mohseni; Shimels Hussien Mohammed; Shahab Alizadeh
Journal:  PLoS One       Date:  2021-03-19       Impact factor: 3.240

Review 5.  Sex Hormone-Binding Globulin (SHBG) as an Early Biomarker and Therapeutic Target in Polycystic Ovary Syndrome.

Authors:  Xianqin Qu; Richard Donnelly
Journal:  Int J Mol Sci       Date:  2020-11-01       Impact factor: 5.923

Review 6.  Effect of Sex Hormone-Binding Globulin on Polycystic Ovary Syndrome: Mechanisms, Manifestations, Genetics, and Treatment.

Authors:  Chuan Xing; Jiaqi Zhang; Han Zhao; Bing He
Journal:  Int J Womens Health       Date:  2022-02-02

7.  Matrix metalloproteinase-9 increases and Interleukin-10 reduces with increase in body mass index in polycystic ovary syndrome: A cross-sectional study.

Authors:  Angel Mercy Sylus; Hanumanthappa Nandeesha; Thiagaraju Chitra
Journal:  Int J Reprod Biomed       Date:  2020-08-19

8.  Gingival crevicular fluid levels of visfatin in patients with chronic periodontitis and polycystic ovary syndrome.

Authors:  Forouzan Saljoughi; Khadijeh Nasri; Mojtaba Bayani
Journal:  Obstet Gynecol Sci       Date:  2019-12-11

Review 9.  Polycystic Ovary Syndrome in Insulin-Resistant Adolescents with Obesity: The Role of Nutrition Therapy and Food Supplements as a Strategy to Protect Fertility.

Authors:  Valeria Calcaterra; Elvira Verduci; Hellas Cena; Vittoria Carlotta Magenes; Carolina Federica Todisco; Elisavietta Tenuta; Cristina Gregorio; Rachele De Giuseppe; Alessandra Bosetti; Elisabetta Di Profio; Gianvincenzo Zuccotti
Journal:  Nutrients       Date:  2021-05-28       Impact factor: 5.717

10.  Effects of serum irisin, neuregulin 4, and weight management on obese adolescent girls with polycystic ovary syndrome.

Authors:  Shunshun Cao; Yangyang Hu
Journal:  Biosci Rep       Date:  2021-09-30       Impact factor: 3.840

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.